However, if this finding holds true in a statistically relevant sample size, it can form a basis for novel therapeutic drug design for inhibiting arginase II or its targets for treatment of TN breast cancer, which are usually very aggressive in nature with limited therapeutic options. This evidence concerns the gene ARG2 and breast carcinoma.